Additionally, we included the PD-1 blocking mAb EH12.2H7 (BioLegend) into our testing as several ex vivo studies recently suggested that blockade of TIGIT in the tumor microenvironment synergizes with the blockade of other CR inhibitors [32–34]. Here, PDCD1 is linked to neoplasm.